Fujirebio at a glance

Founded in 1950

- 75 years pioneering in vitro diagnostics (IVD) innovation and biomarker development

30+ years’ experience

in groundbreaking neurological disease diagnostics

First FDA-cleared blood test

to identify patients with amyloid pathology associated with Alzheimer's disease  (2025)

#1 Worldwide in neurological disease diagnostics 

Leading CDMO provider

for neurological and oncologic disease diagnostics

1,200+ employees

globally across Asia, Europe, and the Americas

Global research & development teams 

across Asia, Europe, and the US specializing in biomarker discovery

Manufacturing facilities

in Asia, Europe, and the US

More than 12%

of base revenue invested in R&D

Open business model

encourages CDMO partnership and diagnostic content sharing over competition

Strategic acquisitions

Centocor Diagnostics (1998), CanAg Diagnostics (2006), Innogenetics (2010), Fluxus and ADx NeuroSciences (2022), and Plasma Services Group (2025)

Part of the H.U. Group

- a leading Japanese healthcare company

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.